The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
It’s eight o’clock on a Tuesday morning and I’m wobbling across my bedroom like a tentative toddler. The floor dips beneath ...
During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
The shutdown, now in its fifth week, halted funding for Medicare’s telehealth program, leaving many patients without vital services.
Researchers used supramolecular nanoparticles to repair the brain’s vascular system and reverse Alzheimer’s in mice. Instead ...
The experimental pill ALZ-801 slowed memory decline by 50% and reduced brain shrinkage in early Alzheimer's patients with ...
A phase 2 clinical trial published in the Journal of Alzheimer’s Disease suggests that low-dose THC-CBD extract may improve ...
If approved by voters, the $3 billion investment could spark groundbreaking discoveries in Texas labs and reshape how the ...
Organizations like Eagle Forum and Grassroots America say constitutional amendments funding water projects and dementia ...
A new study is reviving hope that a twice-daily pill can slow down Alzheimer's in people whose genes put them at high risk ...
Richard Oakley of the Alzheimer's Society spoke to Newsweek about why now is an "exciting time" in the battle against the ...
The Haunt for the Cure haunted house in Paynesville, MN, is scaring up donations to fight Alzheimer’s. Founded by Chelsea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback